Recent medications developed for EGFR mutations have improved overall survival and tumor control, and the fact that EGFR-TKI is able to penetrate the blood–brain barrier [27,28,29] could have a profound effect on the formulation of treatment strategies. This evidence concerns the gene EGFR and neoplasm.